

# XBI

## State Street SPDR S&P Biotech ETF

### Analyst Report

XBI is one of a handful of biotech ETFs available, offering exposure to a corner of the market that can perform well during periods of consolidation and is capable of big jumps in the event of major drug approvals. XBI focuses on a narrow sector of the health care sector, and as such is probably too precise for most investors seeking to construct a long-term portfolio. However, this ETF can be useful for those seeking to fine tune exposure or for those bullish on the sector over the long run. XBI focuses exclusively on American stocks, and primarily consists of mid cap and small cap securities. XBI's portfolio is somewhat limited, though the equal-weighted methodology of the underlying index ensures that assets are balanced across all components. That feature can be particularly important in the biotech space, where specific companies are capable of turning in big gains over short periods of time. PBE and IBB are other ETF options for biotech exposure; those considering this sector should take a close look at depth of exposure and weighing methodology, as these factors can have a major impact on the risk and return profiles achieved.

### ESG Themes and Scores

3.7/10

ESG Rate

1.55%

Global Percentile

3.42%

Peer Percentile

### Performance Data

	XBI	ETF Database Category Average	Factset Segment Average
1 Month	7.67%	5.25%	8.37%
3 Month	13.31%	6.42%	9.98%
YTD Return	15.41%	3.28%	17.07%
1 Year Return	70.86%	29.44%	59.10%
3 Year Return	17.29%	6.61%	12.84%
5 Year Return	1.03%	0.68%	3.63%

### Top 5 Holdings

Symbol	Holding	% Assets
TGTX	TG Therapeutics, Inc.	2.03%
TVTX	Traverse Therapeutics, Inc.	2.03%
TWST	Twist Bioscience Corp.	1.96%
ALKS	Alkermes Public Limited Company	1.77%
RVMD	Revolution Medicines, Inc.	1.75%

### Vitals

Issuer	State Street
Brand	SPDR
Structure	ETF
Expense Ratio	0.35%
Inception	Jan 31, 2006
Index Tracked	S&P Biotechnology Select Industry

### ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Growth
Region (General)	North America
Region (Specific)	U.S.

### FactSet Classifications

Segment	Equity: U.S. Biotechnology
Category	Sector
Focus	Health Care
Niche	Biotechnology
Strategy	Equal
Weighting	Equal

